CLINICAL_TRIALS
trial_result
· 2025-11-14
Clinical Trial Update: Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 [Phase 1]
Summary
A Phase 1 study of EO-3021 in adults with CLDN18.2-expressing solid tumors was terminated; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Elevation Oncology | Conditions: Stomach Neoplasm, Gastrointestinal Neoplasms | Phase 1 | Status: TERMINATED | Results posted: 2025-11-14